Chong Wei,1,* Mei Zhang,2,* Danqing Zhao,1 Wei Zhang,1 Yan Zhang2 

1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Hematology, Beijing Longfu Hospital, Beijing, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Wei Zhang, Email vv1223@vip.sina.com Yan Zhang, Email zhangyan7217@sina.com

Abstract: Glofitamab, a CD20×CD3 T-cell–engaging bispecific monoclonal antibody, has emerged as a promising therapeutic agent for relapsed/refractory B-cell non-Hodgkin lymphoma. The advent of chimeric antigen receptor T-cell therapy and T-cell-engaging bispecific antibodies has also stimulated growing interest in their potential application in autoimmune diseases. Here, we report a case of diffuse large B-cell lymphoma (DLBCL) in a patient with a long-standing history of antisynthetase syndrome (ASyS). The patient achieved complete remission of lymphoma with third-line glofitamab therapy after failure of first-line R-CHOP and second-line polatuzumab vedotin combined with lenalidomide. Remarkably, her ASyS symptoms, which had been refractory to multiple immunosuppressive agents (cyclosporine, methotrexate, hydroxychloroquine) and targeted therapies (tofacitinib, baricitinib), also resolved following glofitamab treatment. This case underscores the potential of glofitamab not only as an effective treatment for refractory DLBCL but also as a novel therapeutic strategy for concomitant autoimmune manifestations, warranting further investigation in the context of autoimmune disorders.

Keywords: diffuse large B-cell lymphoma, T-cell-engaging bispecific antibody, glofitamab, antisynthetase syndrome